ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2025
Toxic epidermal necrolysis associated with immune checkpoint inhibitors for bladder cancer: A case report.
Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Immune checkpoint inhibitors (ICIs) play a significant role in tumor treatment, but the immune-related adverse events (irAEs), which brings about have also attracted much attention. Among them, toxic epidermal necrolysis (TEN) is one of the most severe skin toxic reactions. This article reports a case of a bladder cancer patient who developed TEN after receiving ICIs treatment. The male patient was diagnosed with bladder cancer in November 2023. On April 29, 2024, he was admitted to the Third Hospital of Changsha for antitumor treatment. In May 2024, he developed immune-related myocarditis after treatment with toripalimab. On July 6, 2024, the patient switched to envafolimab treatment, and on July 16, he developed rashes and eventually progressed to TEN. After treatment with glucocorticoids and related symptomatic measures, the patient improved. TEN is a rare but serious irAE in ICIs treatment. Suspected patients should be intervened early, and patients who have already developed it should be actively treated, in order to enhance the understanding and management of TEN caused by ICIs treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.